Abstract
COVID-19 is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and declared by the World Health Organization a global public health emergency. Among the severe outbreaks across South America, Uruguay has become known for curtailing SARS-CoV-2 exceptionally well. To understand the SARS-CoV-2 introductions, local transmissions, and associations with genomic and clinical parameters in Uruguay, we sequenced the viral genomes of 44 outpatients and inpatients in a private healthcare system in its capital, Montevideo, from March to May 2020. We performed a phylogeographic analysis using sequences from our cohort and other studies that indicate a minimum of 23 independent introductions into Uruguay, resulting in five major transmission clusters. Our data suggest that most introductions resulting in chains of transmission originate from other South American countries, with the earliest seeding of the virus in late February 2020, weeks before the borders were closed to all non-citizens and a partial lockdown implemented. Genetic analyses suggest a dominance of S and G clades (G, GH, GR) that make up >90% of the viral strains in our study. In our cohort, lethal outcome of SARS-CoV-2 infection significantly correlated with arterial hypertension, kidney failure, and ICU admission (FDR < 0.01), but not with any mutation in a structural or non-structural protein, such as the spike D614G mutation. Our study contributes genetic, phylodynamic, and clinical correlation data about the exceptionally well-curbed SARS-CoV-2 outbreak in Uruguay, which furthers the understanding of disease patterns and regional aspects of the pandemic in Latin America.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All the work at the Laboratorio de Biologia Molecular AEPS was supported by internal funding from the Asociacion Espanola Primera en Salud. SD is supported by the Fonds National de la Recherche Scientifique (FNRS, Belgium). RD was partially supported by the National Institute of Health (NIH) grant 1R01AI122953. AH, CM, and PZ are supported by the Genome Technology Center, and in part by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The molecular lab at the Asociacion Espanola Primera en Salud (AEPS) is a fully accredited clinical lab, regulated by the Uruguayan Ministry of Health (Ministerio de Salud Pubica, MSP). Sampling was done according to the regional IRB guidelines and the recommendations of the MSP. Our study was evaluated by the commission of bioethics and ethics in research of the AEPS, headed by Fernando Garcia [14-16]. IRB approval was waived, because the genetic analysis was restricted to the virus and not the host, and clinical correlation analyses were done on fully de-identified samples (UY IDs and GISAID IDs were given by the Uruguayan and New York research teams, respectively, and are not traceable to any medical record number). The participants provided informed oral consent, and the data were analyzed anonymously. For participants <18 years of age, formal written or verbal consent was obtained from the parent/guardian at sampling, and data were kept anonymously for the entire study. The molecular clinical lab at AEPS is accredited for diagnostic RT-PCR tests for SARS-CoV-2 (COVID-19) in Uruguay.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Shared first authors
Supplemental Methods added
Data Availability
All data referred to in the manuscript are fully available without restriction, and a summary is provided in Table S1 of the manuscript. All SARS-CoV-2 sequences are available from the GISAID database (accession numbers listed in Table S1).
